Deciphera Pharmaceuticals (DCPH) Stock Price
Deciphera Pharmaceuticals Price
Over the last 4 years Deciphera Pharmaceuticals grew revenue by 59.9% annually, reaching 163.36 M USD. For Deciphera Pharmaceuticals, the net margin of -119.3% is up versus -766.0% a few years ago.
Deciphera Pharmaceuticals stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Deciphera Pharmaceuticals over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Deciphera Pharmaceuticals stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Deciphera Pharmaceuticals's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Deciphera Pharmaceuticals Price |
|---|
Deciphera Pharmaceuticals Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Deciphera Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | 25.00 | 42.00 | 96.00 | 134.00 | 163.00 | 204.00 | 271.00 | 379.00 | 531.00 | 381.00 | 610.00 |
| – | – | – | – | – | 68.00 | 128.57 | 39.58 | 21.64 | 25.15 | 32.84 | 39.85 | 40.11 | -28.25 | 60.10 |
| – | – | – | – | 96.00 | 97.62 | 96.88 | 93.28 | 97.55 | 97.55 | 97.55 | 97.55 | 97.55 | 97.55 | 97.55 |
| 159.00 | 159.00 | 159.00 | 159.00 | 24.00 | 41.00 | 93.00 | 125.00 | 159.00 | 198.99 | 264.35 | 369.70 | 517.97 | 371.65 | 595.03 |
| -17.00 | -25.00 | -50.00 | -104.00 | -200.00 | -271.00 | -300.00 | -182.00 | -210.00 | -203.00 | -271.00 | -379.00 | -531.00 | -381.00 | – |
| – | – | – | – | -800.00 | -645.24 | -312.50 | -135.82 | -128.83 | -99.51 | -100.00 | -100.00 | -100.00 | -100.00 | – |
| -19.00 | -25.00 | -50.00 | -99.00 | -191.00 | -266.00 | -296.00 | -178.00 | -194.00 | -168.00 | -132.00 | -49.00 | 49.00 | -5.00 | 134.00 |
| – | 31.58 | 100.00 | 98.00 | 92.93 | 39.27 | 11.28 | -39.86 | 8.99 | -13.40 | -21.43 | -62.88 | -200.00 | -110.20 | -2,780.00 |
| 4.00 | 12.00 | 17.00 | 35.00 | 43.00 | 56.00 | 58.00 | 76.00 | 85.00 | 85.00 | 85.00 | 85.00 | 85.00 | 85.00 | 85.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Deciphera Pharmaceuticals generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Deciphera Pharmaceuticals retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Deciphera Pharmaceuticals's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Deciphera Pharmaceuticals has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Deciphera Pharmaceuticals's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Deciphera Pharmaceuticals stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Deciphera Pharmaceuticals Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Deciphera Pharmaceuticals business model & stock analysis
Deciphera Pharmaceuticals SWOT Analysis
Strengths
Deciphera Pharmaceuticals Inc has a strong portfolio of innovative cancer therapeutics, developed through extensive research and clinical trials.
The company benefits from a highly skilled and experienced management team, with deep expertise in the biopharmaceutical industry.
Deciphera Pharmaceuticals Inc has secured strong financial backing, allowing it to invest in research and development initiatives.
Weaknesses
As a relatively small biopharmaceutical company, Deciphera Pharmaceuticals Inc may face challenges in competing with larger, more established players in the industry.
The company's success heavily relies on the successful development and regulatory approval of its pipeline products, which may involve considerable time and investment.
Deciphera Pharmaceuticals Inc operates in a highly regulated industry, subject to strict compliance requirements and potential delays in product commercialization.
Opportunities
The rising global prevalence of cancer presents a significant market opportunity for Deciphera Pharmaceuticals Inc to address with its innovative therapies.
Expanding partnerships and collaborations with research institutions and biopharmaceutical companies can further enhance Deciphera Pharmaceuticals Inc's research capabilities and broaden its product pipeline.
The continuous advancements in precision medicine and targeted therapies offer potential for Deciphera Pharmaceuticals Inc to develop personalized treatment options.
Threats
Deciphera Pharmaceuticals Inc faces intense competition from both established pharmaceutical companies and emerging biotechnology firms with similar drug candidates.
The ever-evolving regulatory landscape and potential changes in healthcare policies may impact the company's ability to successfully navigate the drug development and commercialization process.
Disruptions to the global supply chain, such as those caused by the COVID-19 pandemic, can adversely affect Deciphera Pharmaceuticals Inc's operations and ability to meet demand.
Deciphera Pharmaceuticals Segments
Deciphera Pharmaceuticals Revenue by Segment (1/2)
3 Years
Max
Details
Deciphera Pharmaceuticals Revenue by Segment (2/2)
3 Years
5 Years
Max
Details
Deciphera Pharmaceuticals Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Deciphera Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio
Deciphera Pharmaceuticals annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Deciphera Pharmaceuticals shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Deciphera Pharmaceuticals Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/1/2024 | -0.60USD | 44.03 MUSD | 2024 Q1 |
| 2/5/2024 | -0.60USD | 45.99 MUSD | 2023 Q4 |
| 8/2/2023 | -0.58USD | 37.09 MUSD | 2023 Q2 |
| 5/2/2023 | -0.59USD | 35.40 MUSD | 2023 Q1 |
| 2/6/2023 | -0.59USD | 35.36 MUSD | 2022 Q4 |
| 11/3/2022 | -0.59USD | 33.65 MUSD | 2022 Q3 |
| 8/4/2022 | -0.67USD | 30.96 MUSD | 2022 Q2 |
| 5/4/2022 | -0.92USD | 26.83 MUSD | 2022 Q1 |
| 2/8/2022 | -1.41USD | 23.64 MUSD | 2021 Q4 |
| 11/2/2021 | -1.30USD | 23.71 MUSD | 2021 Q3 |
EESG©
Eulerpool ESG Scorecard© for the Deciphera Pharmaceuticals stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Deciphera Pharmaceuticals shareholder structure
| % | Name |
|---|---|
28.18447% | |
6.80464% | |
6.11333% | |
5.64489% | |
5.62583% | |
5.16618% |
Deciphera Pharmaceuticals Executives and Management Board
Mr. Steven Hoerter
(52)President, Chief Executive Officer, Director · since 2018
Dr. Matthew Sherman
(67)Executive Vice President, Chief Medical Officer
Mr. Thomas Kelly
(52)Chief Financial Officer, Executive Vice President, Treasurer
Mr. Daniel Flynn
(69)Founder, Executive Vice President, Chief Scientific Officer · since 2003
Mr. Daniel Martin
(48)Senior Vice President, Chief Commercial Officer
Deciphera Pharmaceuticals Supply Chain
Deciphera Pharmaceuticals Supply Chain
Correlation: how closely stock prices move together
| # | Name | 1M | 3M | 6M | 1Y | 2Y | Trend |
|---|---|---|---|---|---|---|---|
| 1 | 0.40 | -0.25 | -0.28 | 0.67 | 0.81 |
Frequently asked questions about Deciphera Pharmaceuticals
The business model of Deciphera Pharmaceuticals Inc revolves around developing and commercializing targeted therapeutics for the treatment of cancer. With a primary focus on kinase inhibitors, Deciphera Pharmaceuticals aims to address unmet medical needs and improve patient outcomes. The company prioritizes the discovery and development of small molecule drugs, leveraging its proprietary Kinase Switch Control Inhibitor Platform. By combining innovative science, strategic partnerships, and rigorous clinical research, Deciphera Pharmaceuticals aims to bring transformational therapies to patients living with cancer.
Deciphera Pharmaceuticals stock
Deciphera Pharmaceuticals Peer Group
Deciphera Pharmaceuticals Ticker
Deciphera Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Deciphera Pharmaceuticals
Our stock analysis for Deciphera Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Deciphera Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.